Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

15.88 -0.27 (-1.67%)
Streaming Delayed Price Updated: 1:25 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Medical Devices & Supplies - Specialty Stocks Q1 Teardown: Bausch + Lomb (NYSE:BLCO) Vs The Rest
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty... 
Via StockStory
News headline image
3 Profitable Stocks We’re Skeptical Of
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript ↗
Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript 
Via The Motley Fool
Bausch + Lomb Corp (NYSE:BLCO) Beats Q1 Estimates, Raises Full-Year Guidance ↗
Via Chartmill
Bausch + Lomb Corp (NYSE:BLCO) Reports Mixed Q4 2025 Results: Revenue Beat, EPS Miss ↗
Via Chartmill
News headline image
Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026
Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q1 CY2026, with sales up 9.4% year on year to $1.24 billion. The company’... 
Via StockStory
News headline image
Bausch + Lomb (BLCO) Q1 Earnings Report Preview: What To Look For
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before the bell. Here’s what to expect. Bausch + Lomb beat analysts’ reve... 
Via StockStory
News headline image
Bausch Lomb BLCO Q2 2025 Earnings Transcript ↗
Bausch Lomb BLCO Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Bausch + Lomb (BLCO) Q3 2025 Earnings Transcript ↗
Bausch + Lomb (BLCO) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript ↗
Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Initial Public Offering
News headline image
3 Cash-Burning Stocks We Keep Off Our Radar
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy
News headline image
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron... 
Via StockStory
News headline image
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & Supplies - Specialty Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and... 
Via StockStory
News headline image
3 Reasons BLCO is Risky and 1 Stock to Buy Instead
Even during a down period for the markets, Bausch + Lomb has gone against the grain, climbing to $16.01. Its shares have yielded a 10.4% return over the last... 
Via StockStory
Topics Bankruptcy
News headline image
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story ↗
Bausch + Lomb, a global leader in eye health products and surgical devices, reported a recent insider buy amid ongoing sector activity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Billboard Giant Posts $1.6 Billion Revenue as $20.5 Million Bet Makes It a Top Portfolio Holding ↗
This outdoor advertising firm operates a vast network of displays across the Americas and Europe, serving a diverse global client base. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position ↗
Bausch + Lomb provides eye health products and surgical devices globally, serving both healthcare professionals and consumers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know
Via StockStory
Topics Earnings Economy
News headline image
2 Profitable Stocks Worth Investigating and 1 We Ignore
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
Via Finterra
Topics Economy Initial Public Offering Retirement
News headline image
5 Revealing Analyst Questions From Bausch + Lomb’s Q4 Earnings Call
Bausch + Lomb’s fourth quarter showed strong revenue growth but fell short on non-GAAP profit expectations, prompting a modestly negative market reaction. Management attributed the performance to... 
Via StockStory
Topics Earnings
News headline image
3 Small-Cap Stocks We Steer Clear Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus
Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43... 
Via StockStory
News headline image
Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue
Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43... 
Via StockStory
News headline image
Bausch + Lomb (BLCO) Q4 Earnings: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market hours. Here’s what to look for. 
Via StockStory
Topics World Trade
News headline image
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
Bausch + Lomb’s 24.2% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $16.93 per share. This was partly thanks to its solid quarterly results, and... 
Via StockStory
Topics Bankruptcy Stocks
News headline image
1 Healthcare Stock to Research Further and 2 Facing Headwinds
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare... 
Via StockStory
Topics Stocks
News headline image
3 Stocks Under $50 That Fall Short
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
News headline image
3 Cash-Burning Stocks We’re Skeptical Of
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
Via StockStory
Topics Bankruptcy
News headline image
1 Profitable Stock to Keep an Eye On and 2 We Question
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.